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ABSTRACT: The longitudinal association between glycated hemoglobin (HbA 1c) and different courses of depressive
symptoms is understudied. This study aimed to identify different trajectories of depressive symptoms and investigate
the relation of HbA1c with the risk of increasing and high-stable depressive symptoms. In the China Health and
Retirement Longitudinal Study, depressive symptoms were measured using the 10-item Center for Epidemiological
Studies-Depression scale in three visits (years: 2011, 2013 and 2015) among 9804 participants (mean age
60.0 ±9.0 years). Group-based trajectory modeling was used to identify trajectories of depressive symptoms. HbA 1c
was measured at baseline and categorized five groups according to the respective quintile. Multinomial logistic
regression was fitted to examine this relationship. Four distinct trajectories of depressive symptoms were identified:
low symptoms (n=6401, 65.29%); decreasing symptoms (n=1362, 13.89%); increasing symptoms (n=1452, 14.81%);
and high symptoms (n=1452, 14.81%). Adjusting for demographic, health-related, and cognitive factors, the risk ratio
(95% confidence interval) pertaining to the highest HbA 1c (Quintile 5) for decreasing, increasing, and high symptoms
of depression versus low symptoms was 1.01 (0.82-1.25), 1.12 (0.92-1.36), and 1.39 (1.04-1.86) compared with the lowest
HbA1c (Quintile 1), respectively. We observed a J-shaped relationship between HbA1c and high depressive symptoms,
with the lowest risk at a HbA1c concentration of 5.0%. In summary, in this large population-based cohort, high levels
of glycated hemoglobin concentrations were associated with a higher risk of increasing and high-stable symptoms of
depression.
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Depression symptoms are highly prevalent and impact the
quality of life of those struggling from them [1].
Especially, in China, the prevalence of depressive
symptoms among the elderly has been reported to be up
to 22.7% [2]. Moreover, depressive symptoms that
increase over time are also associated with a range of
adverse outcomes, including cardiovascular diseases [3,

4], dementia [5] and all-cause mortality [6].
Understanding risk factors attributed to depressive
symptoms is a major public health priority; however,
potential risk factors for depression symptoms remain
unclear.
Several cohort studies [7-9] and meta-analysis [1012] have revealed that depressive symptoms were
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associated with a high risk of diabetes mellitus.
Additionally, a recent meta-analysis also shows that
diabetes mellitus increased the risk of depression by 25%
[13]. This suggests that the association between
depressive symptoms and diabetes mellitus is more
complex and may be bidirectional[8]. However, in most
studies, depressive symptoms are assessed at a single
point time (at baseline), and hence these studies may not
have fully captured the longitudinal pattern of depressive
symptoms.
Glycated hemoglobin (HbA1c) is considered as the
gold standard measurement of glycemic control for
diabetes mellitus patients, reflecting glucose exposure
over the previous two to three months[14]. Previous
studies found HbA1c is associated with depressive
symptoms [15, 16]. Furthermore, these studies neglect the
relapsing and remitting nature of depressive symptoms.
However, very few studies have provided information that
describes the relationship between HbA1c and the
longitudinal pattern of depressive symptoms in the
Chinese population.
Therefore, the aims of this study were to use repeated
measures of depressive symptoms in three visits from
China Health and Retirement Longitudinal Study
(CHARLS), a nationwide representative cohort study, to
identify the different trajectories of depressive symptoms,
and investigate a possible link between HbA1c and the
trajectory of depressive symptoms. We hypothesize that
high levels of HbA1c is associated with increasing and
high-stable depressive symptoms.
MATERIALS AND METHODS
Study design and population
CHARLS is a population-based, prospective cohort study
of 17708 middle-aged and elderly (main respondents ≥45
years) individuals from 150 counties within 28 provinces
in China[17]. The first visit was accomplished in 2011
(visit 1), and subsequently two follow-up visits carried out
after that, each nearly two years apart (visit 2 in 2013, visit
3 in 2015). The present analysis was limited to 11847
participants who agreed to perform blood examinations in
the visit 1. Out of those participants, 11532 participants
who stored whole-blood samples were available for
measurement of glycated hemoglobin or fasting glucose.
Additionally, 1521 participants were excluded due to
incomplete data on Center for Epidemiologic Studies
Depression Scale (CES-D) during the 2011-2015 period,
as well as 207 main respondents’ spouses who were under
45 years are excluded (Supplementary Fig. 1). Our final
sample size was 9804 persons. The study protocol was
approved by the institutional review board of Peking
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University. All participants provided written informed
consent.
Assessment of depressive symptoms
Depressive symptoms were evaluated using the 10-item
Center for Epidemiologic Studies Depression Scale (CESD) [18]. Participants were asked how often they had
experienced any of the ten symptoms listed during the past
week. The answers for the 10 questions were ranged on a
scale from: rarely (0-1 day); to some days (1-2 days); to
occasionally (3-4 days); and to most of the time (5-7
days). Scores ranged from 0 for rarely to 3 points for most
of the time were assigned for each item and the total
scores were calculated and ranged from 0 to 30. CES-D
had been shown good validity and reliability in the
CHRLS [19]. For the current analysis, missing CES-D
exceeding 2 items were excluded. We only included
participants who had complete assessments of depression
at visits 1, and at least had a one-time assessment at visits
2 or 3.
Measurement of glycated hemoglobin
A specimen of whole blood was stored at -80 ◦C in a deep
freezer and sent to the Youanmen Center for Clinical
Laboratory of Capital Medical University. Total HbA1c
was measured using standard methods of boronate affinity
high performance liquid chromatography. The coefficient
of variation of within assay and between assay was 1.90%
and 2.10%, respectively. The detection limits of the assay
were ranged from 0.0% to 40.0%. Detailed information
regarding blood sample collection, processing,
transportation, storage, the technicalities of the blood
analysis, as well as the quality control and the external
quality assessment for the laboratory has been described
in the CHALRS Blood Sample Users’ Guide
(http://charls.pku.edu.cn/uploads/document/2011-charlswave1/application/blood_user_guide_en_20140429.pdf).
Covariates
Sociodemographic information, lifestyle behaviors and
medical history were obtained using a face-to-face
standard questionnaire and physical examination [17].
The sociodemographic characteristics included age,
gender, living area (urban and rural), education and
marital status (married and unmarried). Self-reported
education was coded as a four levels factor (< primary
school, primary school, middle school, and ≥ high
school). Each participant was asked two questions: “Have
you smoked at least 100 cigarettes in your lifetime?” and
“Do you currently smoke cigarettes, even occasionally?
The options for possible answer to the questions were
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either if it was true or not. Smoking status consisted of
never, former smoker, or current smoker. Alcohol
consumption was determined from one question: “How
often did you drink alcoholic beverages in the past?” The
answer included never, <1, and ≥1 time/month. Selfreported physician diagnosed diseases included cardiac
diseases, stroke, hypertension, diabetes mellitus,
dyslipidemia and lung diseases. Antidepressant drugs
were recoded and updated during 2011-2015. Trained and
certiﬁed health professionals conducted a physical
examination. Weight was measured using the OmronTM
HN-286 scale, and height was measured using SecaTM213
stadiometer. Body mass index (BMI) was calculated as
weight in kilograms divided by height in meters squared.
Obesity was defined as those who had a BMI over 28.0
kg/m2 [20]. Blood pressure was measured using the
OmronTM HEM-7200 Monitor. Three times blood
pressure measurements were taken after the participants
were seated, and rested quietly for >5 minutes and the
average value was obtained. Cognition scores was
consisted of immediate and delayed recall of a 10-word
list (20 points), serial 7 subtractions (5 points), orientation
(1 point each for year, month, date, day of the week, and
season) and drawing a picture (1 point). Then, total scores
were calculated, which were ranged from 0 to 31, where
higher scores indicated better cognitive function[17].
Overnight fasting blood samples were collected and tested
for high-density lipoprotein cholesterol (HDL-C), lowdensity lipoprotein cholesterol (LDL-C), glucose, highsensitivity C-reactive protein (hs-CRP), and creatinine by
standard methods [21]. The estimated glomerular
ﬁltration rate (eGFR) was calculated based on the Chronic
Kidney Disease Epidemiology Collaboration equation
(CKD-EPI-2009) [22].
Statistical analysis
Trajectories of depressive symptoms were the main
outcomes. Trajectories of depressive symptoms were
determined using group-based trajectory modeling
(GBTM), an application of ﬁnite mixture modeling to map
the developmental course of symptoms over time or
age[23, 24]. We conducted a censored normal distribution
model using Stata traj plugin [25] to estimate the mean
trajectories of CES-D scores (measured at year 0, 2, 4)
across three visits. The number and the shape of
trajectories of depressive symptoms were identified based
on a priori. Firstly, the average posterior probabilities of
each trajectory group were ≥0.70 and the sample size was
≥5.0% of the population [23]. Secondly, nonsignificant
cubic and quadratic terms were removed from trajectories
in each model, but linear parameters were retained
irrespective of significance. Third, Bayesian Information
Criterion (BIC) value and log Bayes factor was calculated
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and used to determine the best numbers and shapes of the
trajectories. The value of log Bayes factor ≥10 was
considered a “very strong” indicator where the more
complex model was superior to with fewer
trajectories[23]. Later, trajectories of depressive
symptoms were plotted over follow-up time.
The exposure variable was glycated hemoglobin, and
categorized according to quintiles as follows: Quintile 1
(≤4.8%); Quintile 2 (4.9-5.0%); Quintile 3 (5.1-5.2%);
Quintile 4 (5.3-5.5%); and Quintile 5 (≥5.6%). Linear
trends across the 5 groups were evaluated using the
generalized linear model. Multinomial logistic regression
was used to calculate the adjusted risk ratios (RR) of
decreasing, increasing, and high symptoms of depression
compared with low symptoms according to glycated
hemoglobin categories, while simultaneously adjusting
for confounding covariates. For confounder adjustment, 5
models were evaluated. Model 1 was minimally adjusted
for age and gender. Model 2 was adjusted for the
additional socio-demographics of marital status,
educational level, living area, and health behaviors of
smoking and alcohol frequency. Model 3 was further
adjusted the baseline health conditions including
hypertension, diabetes mellitus, cardiac disease, stroke,
dyslipidemia, lung disease, and obesity. Then, we
sequentially added other covariates, including cardiac
markers (Model 4), baseline cognition scores and
antidepressant use over 4 years (Model 5).
In addition, we evaluated the dose-response
relationship between glycated hemoglobin, as continuous
change, and each trajectory of depressive symptoms using
restricted cubic splines[26] with 4 knots corresponding to
the 5th, 35th, 65th, and 95th percentiles of glycated
hemoglobin distribution. The likelihood-ratio tests were
used to assess whether it exited in a nonlinear trend.
Sensitivity analyses were also conducted: 1) changing
glycated hemoglobin categories of <4.5%, 4.5-5.0%, 5.15.5%, 5.6-6.0%, and >6.0%, respectively; 2) excluding
participants who had treatments for depression or
diabetes; 3) limited to those participants who were free of
depression symptoms (CES-D scores <10[27]) at
baseline. We explored the relationship between glycated
hemoglobin and incidence of depressive symptoms at
visit 3 (year 2015). Lastly, to test whether the associations
differed between gender, gender-specific analyses were
performed for male and female, separately. Subsequently,
a multiplicative term between gender and quantile of
HbA1c was added in the full-adjusted model and the
interaction was tested by a likelihood ratio test.
All analyses were performed with Stata software
(version 14.0; Stata Corp., College Station, TX). A twosided P value <0.05 was considered statistically
signiﬁcant.
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Table 1. Baseline Characteristics of the Study Participants According to the Quintile of Glycated Hemoglobin (HbA 1c).
Characteristic*

Quintile 1
(≤4.8 %)
2258
4.6 ±0.2
58.2 ±9.4
1088 (48.2)
1997 (88.4)
796 (35.3)

Quintile2
(4.9-5.0 %)
1815
5.0 ±0.0
58.4 ±9.1
864 (47.6)
1607 (88.5)
623 (34.3)

Quintile 3
(5.1-5.2 %)
1904
5.1 ±0.1
59.0 ±9.0
873 (45.9)
1700 (89.3)
664 (34.9)

Quintile 4
(5.3-5.5 %)
2022
5.4 ±0.1
59.4 ±8.8
925 (45.7)
1787 (88.4)
695 (34.4)

Quintile 5
(≥5.6 %)
1805
6.4 ±1.2
59.8 ±8.6
801 (44.4)
1609 (89.1)
744 (41.2)

P for
Trend

No. of participants
Glycated hemoglobin, %
<0.001
Age, yr
<0.001
Male gender, no. (%)
0.008
Married, no. (%)
0.587
Urban, no. (%)
<0.001
Educational level, no. (%)
<0.001
<Primary school
974 (43.1)
827 (45.6)
895 (47.0)
1012 (50.0)
839 (46.5)
Primary school
542 (24.0)
379 (20.9)
433 (22.7)
455 (22.5)
406 (22.5)
Middle school
480 (21.3)
427 (23.5)
391 (20.5)
335 (16.6)
371 (20.6)
≥High school
262 (11.6)
182 (10.0)
185 (9.7)
220 (10.9)
189 (10.5)
Smoking status, no. (%)
0.069
Never
1357 (60.1)
1108 (61.0)
1165 (61.2)
1213 (60.0)
1141 (63.2)
Former smoker
189 (8.4)
157 (8.7)
164 (8.6)
176 (8.7)
171 (9.5)
Current smoker
712 (31.5)
550 (30.3)
575 (30.2)
633 (31.3)
493 (27.3)
Alcohol frequency, no. (%)
<0.001
Never
1441 (63.8)
1207 (66.5)
1277 (67.1)
1379 (68.2)
1291 (71.5)
<1 time/month
199 (8.8)
135 (7.4)
155 (8.1)
151 (7.5)
129 (7.1)
≥1 time/month
618 (27.4)
473 (26.1)
472 (24.8)
492 (24.3)
385 (21.3)
Physician diagnosed diseases, no. (%)
Hypertension
487 (21.6)
433 (23.9)
449 (23.6)
528 (26.1)
578 (32.0)
<0.001
Diabetes mellitus
57 (2.5)
43 (2.4)
43 (2.3)
91 (4.5)
337 (18.7)
<0.001
Cardiac diseases
238 (10.5)
200 (11.0)
241 (12.7)
268 (13.3)
283 (15.7)
<0.001
Stroke
46 (2.0)
32 (1.8)
31 (1.6)
41 (2.0)
52 (2.9)
0.079
Dyslipidemia
178 (7.9)
143 (7.9)
183 (9.6)
188 (9.3)
253 (14.0)
<0.001
Lung diseases
227 (10.1)
174 (9.6)
192 (10.1)
224 (11.1)
179 (9.9)
0.559
BMI, kg/m2
23.1 ±3.8
23.3 ±3.8
23.4 ±3.7
23.7 ±4.2
24.6 ±4.1
<0.001
Obesity, no. (%)
463 (20.5)
377 (20.8)
379 (19.9)
421 (20.8)
530 (29.4)
<0.001
Systolic BP, mm Hg
129.9 ±20.4
129.7 ±20.2
129.8 ±20.0
130.5 ±20.8
132.6 ±19.8
<0.001
Diastolic BP, mm Hg
75.6 ±11.7
75.7 ±11.8
75.7 ±11.5
75.6 ±11.7
76.8 ±10.8
0.009
Fasting glucose, mg/dl
100.2 ±19.4
101.7 ±17.0
104.3 ±20.2
107.1 ±20.0
140.3 ±65.3
<0.001
LDL Cholesterol, mg/dl
109.9 ±33.2
115.6 ±33.0
117.6 ±35.9
118.2 ±34.8
122.2 ±36.6
<0.001
HDL Cholesterol, mg/dl
51.6 ±15.4
51.9 ±15.0
50.9 ±14.5
51.9 ±16.0
48.5 ±15.2
<0.001
C-reactive protein, log
0.0 ±1.1
0.1 ±1.0
0.1 ±1.0
0.2 ±1.1
0.4 ±1.1
<0.001
Estimated GFR, ml/min/1.73 m2
93.5 ±14.6
93.1 ±14.1
91.8 ±14.8
92.2 ±14.8
90.9 ±15.2
<0.001
Cognition scores
14.9 ±5.2
15.0 ±5.1
14.6 ±5.2
14.4 ±5.3
14.4 ±5.3
<0.001
Antidepressant use¶, no. (%)
16 (0.7)
8 (0.4)
10 (0.5)
15 (0.7)
14 (0.8)
0.508
*Plus–minus values are means ±SD. Abbreviations: BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; C-reactive protein was measured in mg/l.
¶Antidepressant use was updated by every visit from 2011 to 2015.

RESULTS
Baseline characteristics of the participants according to
the quintile of HbA1c were shown in Table 1. The overall
mean (±SD) HbA1c of the study population was 5.26 ±
0.81 % (5th to 95th percentile ranged from 4.50 to 6.40
%) (Supplementary Fig. 2). The average concentrations
for subjects in the highest quintile (Quintile 5, n=1805),
and lowest quintile (Quintile 1, n=2258) were 4.61 ±
0.22%, 6.40 ± 1.25%, respectively. Compared with the
lowest quintile of HbA1c (Quintile 1), those with the
highest quintile of HbA1c (Quintile 5) were older, and
more likely to be female, living in urban areas, more likely
to have had a higher education, less likely to be a current
smoker or drinker, and more likely to have a higher BMI,
blood pressure, fasting glucose, LDL-C, HDL-C and hsCRP (Table 1). Coexisting conditions were highly
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prevalent among participants who had the highest levels
of HbA1c (Table 1).
During the three visits, data on CES-D scores were
available for 9804, 9360, and 9140 participants,
respectively. 8696 had data suggesting CES-D scores at
all three visits. Firstly, based on a priori, we conducted a
GBTM analysis with 3 trajectories (BIC=-85859.06). We
found 4 trajectories (BIC=-85666.43) were superior to the
model with 3 trajectories. The log Bayes factor was
385.26, revealing that the four-trajectory was the best fit.
Although a model with 5 trajectories (BIC=-85577.58)
was associated with further improvement in model fit (log
Bayes factor=177.7), this model yielded a trajectory with
less than 5% of participants (63.25%; 15.69%; 12.23%;
2.28% and 6.55%, respectively). Therefore, four distinct
trajectories of depressive symptoms were identified in
subsequent analyses. The average posterior probabilities

252

Li H., et al

Glycated Hemoglobin and Trajectories of Depressive Symptoms

of each trajectory group were 0.90, 0.70, 0.71 and 0.83,
respectively.

Figure 1. Trajectories of Depressive Symptoms from 20112015.

increasing or high symptoms over 4 years. Trajectory 1,
termed “low symptoms” (n=6401, 65.29%), which
followed a linear trend (β0=5.10, P<0.001; β1=-0.15,
P<0.001), represented the individuals who maintained a
low CES-D score throughout the follow-up. Trajectory 2,
termed “decreasing symptoms” (n=1362, 13.89%)
followed a quadratic trend (β0=15.50, P<0.001; β1=-2.43,
P<0.001; β2=0.19, P=0.008), in which individuals started
at moderately high scores but then remitted. Trajectory 3,
termed “increasing symptoms (n=1452, 14.81%)” follows
a quadratic trend (β0=9.93, P<0.001; β1=-1.12, P<0.001;
β2=0.61, P<0.001) in which CES-D scores increased
slowly from year 0 to year 2, and then increased quickly
by year 3. Trajectory 4, termed “high symptoms” (n=589,
6.01%) follows a quadratic trend (β0=19.49, P<0.001;
β1=-0.67 P<0.001; β2=0.25 P<0.001), in which
individuals maintained high scores throughout.

As shown in Figure 1, four depressive symptoms
trajectories reflected the patterns of low, decreasing,
Table 2. Risk Ratios for the Association Between Quintile of Glycated Hemoglobin (HbA1c) and
Risk of Trajectories of Depressive Symptoms *
Low symptoms Decreasing symptoms
(n=6401)
(n=1362)
Model 1: Adjusted for age and gender
Quintile 1
1.00 (Reference)

Increasing symptoms
(n=1452)

High symptoms
(n=589)

1.00 (Reference)

1.00 (Reference)

Quintile 2
0.90 (0.75-1.09)
1.07 (0.89-1.28)
0.85 (0.64-1.13)
Quintile 3
1.05 (0.88-1.25)
1.02 (0.85-1.22)
1.08 (0.83-1.41)
Quintile 4
0.97 (0.81-1.16)
1.28 (1.08-1.52)
1.00 (0.77-1.30)
Quintile 5
1.08 (0.90-1.30)
1.18 (0.99-1.42)
1.29 (1.00-1.67)
Model 2: Adjusted for demographics a and health behaviors b
Quintile 1
1.00 (Reference)
1.00 (Reference)
1.00 (Reference)
Quintile 2
0.89 (0.74-1.07)
1.05 (0.88-1.27)
0.83 (0.62-1.1)
Quintile 3
1.04 (0.87-1.25)
1.01 (0.84-1.22)
1.08 (0.83-1.41)
Quintile 4
0.94 (0.78-1.13)
1.26 (1.06-1.50)
0.97 (0.74-1.26)
Quintile 5
1.12 (0.93-1.35)
1.22 (1.02-1.47)
1.37 (1.05-1.77)
Model 3: Adjusted for demographics a, health behaviors b and baseline health conditions c
Quintile 1
1.00 (Reference)
1.00 (Reference)
1.00 (Reference)
Quintile 2
0.89 (0.73-1.07)
1.05 (0.87-1.26)
0.83 (0.62-1.11)
Quintile 3
1.03 (0.86-1.24)
1.00 (0.84-1.21)
1.08 (0.82-1.41)
Quintile 4
0.92 (0.76-1.10)
1.24 (1.04-1.47)
0.93 (0.71-1.22)
Quintile 5
1.07 (0.88-1.29)
1.18 (0.98-1.42)
1.28 (0.97-1.68)
Model 4: Adjusted for demographics a, health behaviors b, baseline health conditions c and cardiac marker d
Quintile 1
1.00 (Reference)
1.00 (Reference)
1.00 (Reference)
Quintile 2
0.88 (0.73-1.06)
1.05 (0.87-1.26)
0.84 (0.63-1.13)
Quintile 3
1.03 (0.86-1.24)
1.00 (0.83-1.20)
1.12 (0.85-1.46)
Quintile 4
0.90 (0.75-1.08)
1.22 (1.02-1.46)
0.97 (0.74-1.27)
Quintile 5
1.05 (0.85-1.28)
1.14 (0.94-1.39)
1.46 (1.09-1.95)
Model 5: Adjusted for demographicsa, health behaviorsb, baseline health conditionsc, cardiac markerd,
antidepressant use and cognition scores
Quintile 1
1.00 (Reference)
1.00 (Reference)
1.00 (Reference)
Quintile 2
0.89 (0.73-1.08)
1.05 (0.87-1.27)
0.84 (0.63-1.13)
Quintile 3
1.02 (0.85-1.23)
0.99 (0.82-1.20)
1.10 (0.84-1.45)
Quintile 4
0.89 (0.74-1.07)
1.21 (1.01-1.44)
0.95 (0.72-1.24)
Quintile 5
1.01 (0.82-1.25)
1.12 (0.92-1.36)
1.39 (1.04-1.86)
*Data was reported as risk ratios (95%CI) from multinomial logistic regression. a Demographic factor were age,
gender, marital status, educational level, and living area. b Health behaviors consisted of smoking, and alcohol
frequency. c Baseline health conditions included hypertension, diabetes mellitus, cardiac disease, stroke,
dyslipidemia, lung disease, and obesity. d Cardiac marker consisted of systolic blood pressure, fasting glucose,
LDL cholesterol, HDL cholesterol, log-transformed C-reactive protein and eGFR.
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Table 3. Risk of Incident Increasing and High Depressive
Symptoms Associated with Glycated Hemoglobin Level.
Glycated
Risk Ratios (95% CI) *
hemoglobin,
Increasing symptoms High symptoms
%
4.5
1.01 (0.89-1.14)
1.10 (0.91-1.33)
4.8
0.99 (0.96-1.03)
1.00 (0.95-1.06)
5.0
1.00
1.00
5.2
1.04 (0.99-1.08)
1.08 (1.01-1.15)
5.5
1.10 (0.99-1.21)
1.22 (1.03-1.43)
5.8
1.14 (1.00-1.30)
1.30 (1.05-1.61)
6.0
1.16 (1.01-1.33)
1.33 (1.05-1.68)
6.2
1.18 (1.02-1.36)
1.35 (1.06-1.72)
6.5
1.20 (1.04-1.40)
1.36 (1.04-1.77)
*Adjusted for age, gender, marital status, educational level, living area,
smoking, alcohol frequency, hypertension, diabetes mellitus, cardiac
disease, stroke, dyslipidemia, lung disease, obesity, systolic blood
pressure, fasting glucose, LDL cholesterol, HDL cholesterol, logtransformed C-reactive protein, estimated GFR, antidepressant use and
cognition scores.

During a 4 year of follow-up, 130 (5.76%),
91(5.01%), 120 (6.30%), 116 (5.74%) and 132 (7.31%)
subjects developed high depressive symptoms across the
quintile of HbA1c, respectively. Corresponding increasing
depressive symptoms were 305 (13.51%), 266 (14.66%),
261 (13.71%), 342 (16.91%) and 278 (15.40%).
Individuals with a high HbA1c were significantly more
likely to have increasing and high depressive symptoms
compared with their counterparts with low HbA1c (Table
2). The RR of highest HbA1c of high depressive symptoms
was 1.37 (95% CI: 1.05-1.77) as compared with those
with the lowest levels of HbA1c after adjusted for
demographics and health behaviors variables. In addition,
we further adjusted for systolic blood pressure, fasting
glucose, LDL cholesterol, HDL cholesterol, logtransformed hs-CRP, eGFR, antidepressant use and
cognition scores, the multivariate-adjusted risk ratios of
high depressive symptoms remained signiﬁcant (RR:1.39,
95% CI:1.04-1.86). Meanwhile, the risk for increasing
symptoms of depression of highest HbA1c (Quintile 5) still
was not statistically signiﬁcant compared with Quintile 1
(adjusted RR: 1.12, 95% CI: 0.92-1.36). The
corresponding Quintile 4 group was at high risk of
increasing symptoms of depression (adjusted RR: 1.21,
95% CI: 1.01-1.44).
We also used restricted cubic splines to estimate the
trend in the risk for increasing and high depressive
symptoms. The spline function for HbA1c conﬁrmed the
nonlinear, J-shaped relationship with the risk of high
depressive symptoms. Whereas the association of HbA1c
concentration with increasing depressive symptoms
appeared to be linear throughout the range from the 5th to
the 95th percentile of HbA1c (Fig. 2). For instance, for a
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HbA1c levels of 6.5% compared to 5%, the adjusted risk
ratios for increasing and high depressive symptoms was
1.20 (95% CI: 1.04-1.40) and 1.36 (95% CI: 1.04-1.77),
respectively (Table 3).

Figure 2. Risk of Incident Increasing and High Depressive
Symptoms Associated with Glycated Hemoglobin Level.
Solid curve represents estimates of the risk ratios. The dashed
lines represent pointwise 95% confidence intervals. HbA1c of
5% was used as the reference because it approximated the
median values. The graphs are truncated at the 5th and 95th
percentiles.

Our results were robust in various sensitivity
analyses. Firstly, results from this analysis using an
alternative HbA1c category was consistent with the
previous results; in particular, high levels of HbA1c
(>6.0%) was still associated with a significantly increased
risk of increasing (RR: 1.36, 95% CI: 1.03-1.79) and high
(RR: 1.73, 95% CI: 1.14-2.63) symptoms of depression.
(Supplementary Fig. 3). Secondly, the results remained
essentially unchanged after excluding these individuals
who had treatments for diabetes or depression
(Supplementary Table 1). Thirdly, we excluded those who
had depressive symptoms at baseline (n=3715), as well as
participants with missing data of CES-D in visits 3 (year
2015) (n=422). The final analytical sample was limited to
5667 persons. During a 4-year follow-up, 1281
(n=22.60%) incident depressive symptoms were
identified. The adjusted risk ratios of the Quintile 4 group
(ranged from 5.3% to 5.5%) compared with the lowest
quantile group of HbA1c was 1.29 (95% CI: 1.12-1.49).
Corresponding risk ratios for the highest HbA1c quantile
was 1.12 (95% CI: 0.95-1.33) (Supplementary Table 2).
Lastly, for male, the risk ratios of high symptoms for
participants in the second and top HbA1c quintile were
0.91 (95%CI: 0.55-1.51) and 1.20 (95% CI: 0.71-2.03),
respectively. Corresponding risk ratios for female were
0.81 (95% CI: 0.56-1.17) and 1.49 (95% CI: 1.04-2.11).
We found a marginal difference in the association of
quantile of HbA1c with different trajectories of depressive
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symptoms between male and female (Likelihood-ratio
test: χ2=18.48, P for interaction=0.102) (Supplementary
Table 3).
DISCUSSION
We observed four trajectories of depressive symptoms
characterized by low, decreasing, increasing, and high
symptoms in a large prospective cohort of 9804
participants during a 4-year follow-up. Individuals with
the highest quintile of HbA1c (≥5.6%) had the higher risk
of developing increasing and high depressive symptoms
compared with those with the lowest quintile (≤4.8%).
Moreover, we observed a J-shaped relation between
HbA1c and the risk of high depressive symptoms, with the
lowest risk at a HbA1c of 5.0% from restricted cubic
splines analysis.
To the best of our knowledge, four trajectories of
depressive symptoms were firstly identified in the middleaged and older Chinese adults. Previously, three
trajectories of depressive symptoms (consistently
minimal, moderate and increasing, and high and
increasing symptoms) were identified with four CES-D
measures from baseline to year 5 among 2488 older adults
from the Health ABC prospective cohort study [28]. Five
trajectories of depressive symptoms (low, decreasing,
remitting, increasing, and high depressive symptoms)
were also observed in the Rotterdam Study [5, 29].
Differences of shape and the number of trajectories of
depressive symptoms were was due to the time of CES-D
measurements as well as the follow-up time. We noted
that, in the current study that, among the 9804 participants
aged ≥60 years, 6.01% of individuals had the increasing
and high-stable symptoms of depression respectively.
Prospective cohort studies had demonstrated that
individuals with increasing or high-stable symptoms of
depression had a higher risk of dementia [5, 28].
Therefore, physicians should pay more attention to these
individuals and treat positively depressive symptoms in
order to reduce the burden of dementia in the clinical
practice.
There has been a sizable literature that reported on the
association between diabetes and elevated depressive
symptoms [8, 13, 15, 16, 30]; however, research related to
the association between HbA1c and the incidence of
depressive symptoms is limited. For example, no
significant association was observed in the English
Longitudinal Study of Aging after adjusted full covariates
(OR: 1.08, 95%: 0.91-1.29 per 1% HbA1c increment)
(Hamer et al., 2011). In addition, in the Health, Aging, and
Body Composition Study, HbA1c ≥7% did not increased
the risk of depressive symptoms (RR: 1.21, 95% CI: 0.941.55), whereas high HbA1c was associated with a two-fold
risk of recurrent depressive symptoms (RR: 2.10, 95% CI:
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1.36-3.22) compared with HbA1c <7% during a mean
follow-up of 5.9 years among older person aged from 7079 years. This indicated that single measures of depressive
symptoms may be inaccurate, and suggests that
depressive symptoms seem to fluctuate over time.
Additionally, a recent study conducted by RavonaSpringer et al. revealed that the long-term variability in
HbA1c was associated with more subsequent depressive
symptoms [31]. This was consisted with our findings.
However, in this study[31], depressive symptoms was
only measured using Geriatric Depression Scale (GDS15) at baseline and the impact of the variability in HbA1c
on the incidence of depressive symptoms was unclear. In
our study, HbA1c was only available at baseline, and the
association between the long-term change of HbA1c and
the longitudinal pattern of depressive symptoms is
required to be validated in a large population-based
longitudinal study.
Another interesting finding was that HbA1c also was
associated with a high risk of an increasing depressive
symptoms trajectory. Previous studies have shown that
poor glycemic control at baseline was associated with
increased risk for the incidence of depressive symptoms
[15, 16, 32]. To confirm the findings, we also repeated the
analysis among the non-depressed individuals and
examined the role of HbA1c as a risk for new-onset
depressive symptoms over a 4-year follow-up period.
However, the highest risk of depression was observed at
HbA1c levels of 5.3-5.5% (Quintile 4), rather than the
highest Quintile (≥5.6 %). This finding had some
discrepancies with previously findings related to the
threshold of HbA1c [16, 33], which may due to the
difference in the study design, the definition of increasing
symptoms of depression, the distribution and
categorization of HbA1c in the study population. Overall,
we found HbA1c was linked to increasing symptoms of
depression. Nonetheless, more research is needed to
examine this association. Increasing symptoms of
depression was meant to be emphasized, which also
reflected glycemic control [32, 34] and increased the risk
of diabetes [35], dementia [5, 28] and all-cause mortality
[29].
Our findings further demonstrated that baseline
HbA1c was associated with increasing and high depressive
symptoms. Results were not affected by further
adjustment for sociodemographic, history of diabetes,
fasting glucose, and other confounders that related to
depressive symptoms. In addition, depressive symptoms
and cognitive decline were coexisting in late-life [36]. The
relationship was robust after adjusting for cognitive
scores. To account for bias due to use of antidepressant
and/or antidiabetic medication, we repeated the analysis
after excluding those relevant participants. The results
remained considerably unaltered. Lastly, a slight stronger
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association between HbA1c and depressive symptoms was
observed among female, however, gender differences
were not statistically significant (P for interaction =
0.102). This may be due to different levels of estrogen
[37]. The findings were consistent with a previously study
conducted in the Nurses’ Health Study cohort [38].
The mechanisms underlying the relationship of
HbA1c with subsequent risks of high symptoms of
depression remain unclear. Firstly, the “vascular
depression” hypothesis may explain the relationship [39];
HbA1c reflects the glycemic control for diabetes patients,
and brain vasculature and the functional area may be
mostly vulnerable to worse glycemic control [40].This
may be related to the process of depression. Secondly,
late-life risk factors, including smoking, obesity, and
chronic diseases were both associated with high HbA1c
and depressive symptoms [41].
Several limitations in our study should be noted. First,
although HbA1c predicted the incidence of high
depressive symptoms, the causal relationship between
HbA1c and depressive symptoms has not been fully
established. Due to this study being observational in
nature, residual confounding could not be fully
eliminated. Besides, the association was based on single
glycated hemoglobin measurements at the baseline as
well as the fact that the relationship of variability in HbA1c
over years, with subsequent increasing and high-stable
depressive symptoms could not be examined. Major
strengths of our study were that it was the largest,
nationwide population-based cohort study, as well it
obtained a high response rate in CES-D measures (89%
for all three visits). Moreover, the study design of
CHARLS was referred to the Health and Retirement
Study [42] and comprehensive and rigorous
measurements of risk factors were collected. This gave us
an opportunity to adjust more potential confounding
variables.
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